Pamela Hair1, Daniel W Goldman2, Jessica Li2, Michelle Petri2, Neel Krishna3, Kenji Cunnion1. 1. Eastern Virginia Medical School Pediatric Research, Department of Pediatrics, Norfolk, VA. 2. Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD. 3. Eastern Virginia Medical School, Department of Microbiology and Molecular Cell Biology, Norfolk, VA.
Abstract
INTRODUCTION: Autoimmune hemolytic anemia (AIHA) is a serious manifestation of systemic lupus erythematosus (SLE) associated with significant morbidity and mortality. In order to more fully understand the causative pathways, we utilized sera from subjects with SLE and active AIHA, or a history of AIHA, to evaluate the classical complement pathway, anti-erythrocyte antibodies, and immune complexes. METHODS: To evaluate antibody-mediated complement activation on the surface of erythrocytes, as occurs in AIHA, blood type O erythrocytes were incubated with sera from 19 subjects with SLE and a history of AIHA. Circulating anti-erythrocyte antibodies and immune complexes were measured with ELISA-based assays. RESULTS: In total, 90% of subjects with SLE and a history of AIHA, but not active clinical hemolysis, had measurable anti-erythrocyte antibodies. Of those with anti-erythrocyte antibody, 53% demonstrated complement opsonization on the erythrocyte surface >twofold above negative control and 29% generated the anaphylatoxin C5a. CONCLUSIONS: For subjects with SLE and a history of AIHA, the persistence of circulating anti-erythrocyte antibodies and resultant erythrocyte complement opsonization and anaphylatoxin generation suggests the possibility that these complement effectors contribute to chronic morbidity and risk of AIHA relapse.
INTRODUCTION:Autoimmune hemolytic anemia (AIHA) is a serious manifestation of systemic lupus erythematosus (SLE) associated with significant morbidity and mortality. In order to more fully understand the causative pathways, we utilized sera from subjects with SLE and active AIHA, or a history of AIHA, to evaluate the classical complement pathway, anti-erythrocyte antibodies, and immune complexes. METHODS: To evaluate antibody-mediated complement activation on the surface of erythrocytes, as occurs in AIHA, blood type O erythrocytes were incubated with sera from 19 subjects with SLE and a history of AIHA. Circulating anti-erythrocyte antibodies and immune complexes were measured with ELISA-based assays. RESULTS: In total, 90% of subjects with SLE and a history of AIHA, but not active clinical hemolysis, had measurable anti-erythrocyte antibodies. Of those with anti-erythrocyte antibody, 53% demonstrated complement opsonization on the erythrocyte surface >twofold above negative control and 29% generated the anaphylatoxin C5a. CONCLUSIONS: For subjects with SLE and a history of AIHA, the persistence of circulating anti-erythrocyte antibodies and resultant erythrocyte complement opsonization and anaphylatoxin generation suggests the possibility that these complement effectors contribute to chronic morbidity and risk of AIHA relapse.
Authors: Wilma Barcellini; Bruno Fattizzo; Anna Zaninoni; Tommaso Radice; Ilaria Nichele; Eros Di Bona; Monia Lunghi; Cristina Tassinari; Fiorella Alfinito; Antonella Ferrari; Anna Paola Leporace; Pasquale Niscola; Monica Carpenedo; Carla Boschetti; Nicoletta Revelli; Maria Antonietta Villa; Dario Consonni; Laura Scaramucci; Paolo De Fabritiis; Giuseppe Tagariello; Gianluca Gaidano; Francesco Rodeghiero; Agostino Cortelezzi; Alberto Zanella Journal: Blood Date: 2014-09-16 Impact factor: 22.113
Authors: Pamela S Hair; Charlene G Echague; Reuben D Rohn; Neel K Krishna; Julius O Nyalwidhe; Kenji M Cunnion Journal: J Transl Med Date: 2012-03-05 Impact factor: 5.531
Authors: Ying Jiang; Hong Jun Zhao; Hui Luo; Bi Juan Li; Zhi Min Zhang; Li Dan Zhao; Xiao Xia Zuo Journal: Front Immunol Date: 2022-06-10 Impact factor: 8.786